217 related articles for article (PubMed ID: 19479615)
1. Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Godley LA
Leuk Lymphoma; 2009 Jun; 50(6):871-2. PubMed ID: 19479615
[No Abstract] [Full Text] [Related]
2. Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
Pieńkowska-Grela B; Rygier J; Woroniecka R; Grygalewicz B; Pastwińska A; Krawczyk P; Ceglerek B; Seferyńska I; Sikorska A; Konopka L
Leuk Lymphoma; 2009 Jun; 50(6):952-65. PubMed ID: 19479611
[TBL] [Abstract][Full Text] [Related]
3. Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.
Lu CM; Zhou L; Feng S; Kohn PH; Qi Z; Yu J
Leuk Lymphoma; 2011 Nov; 52(11):2182-4. PubMed ID: 21718138
[No Abstract] [Full Text] [Related]
4. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
5. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
[TBL] [Abstract][Full Text] [Related]
6. A novel 5-way translocation t(9;11;13;19;22) in a case of chronic-phase chronic myeloid leukemia.
Vaidya S; Joshi D; Ghosh K; Chakrabarti P; Vundinti BR
Hum Pathol; 2013 Oct; 44(10):2365-9. PubMed ID: 23759653
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
Kubota Y; Waki M
Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
[No Abstract] [Full Text] [Related]
8. Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
Bennour A; Ouahchi I; Ben Youssef Y; Zaier M; Laatiri MA; Harrabi I; Meddeb B; Elloumi M; Khelif A; Saad A; Sennana H
Med Oncol; 2012 Jun; 29(2):1151-60. PubMed ID: 21461967
[TBL] [Abstract][Full Text] [Related]
9. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
[TBL] [Abstract][Full Text] [Related]
10. Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Cesar JM; Cabello P; Ferro T; Navarro JL
Cancer Genet Cytogenet; 2006 May; 167(1):74-7. PubMed ID: 16682291
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelogenous leukemia.
O'Brien S; Berman E; Bhalla K; Copelan EA; Devetten MP; Emanuel PD; Erba HP; Greenberg PL; Moore JO; Przepiorka D; Radich JP; Schilder RJ; Shami P; Smith BD; Snyder DS; Soiffer RJ; Tallman MS; Talpaz M; Wetzler M
J Natl Compr Canc Netw; 2005 Nov; 3(6):732-55. PubMed ID: 16316611
[No Abstract] [Full Text] [Related]
13. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.
Albano F; Anelli L; Zagaria A; Coccaro N; Casieri P; Rossi AR; Vicari L; Liso V; Rocchi M; Specchia G
Mol Cancer; 2010 May; 9():120. PubMed ID: 20500819
[TBL] [Abstract][Full Text] [Related]
14. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case.
Zeidan A; Kakati S; Anderson B; Barcos M; Wetzler M
Cancer Genet Cytogenet; 2007 Jul; 176(2):169-71. PubMed ID: 17656263
[No Abstract] [Full Text] [Related]
15. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
Mattison R; Larson RA
Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
[No Abstract] [Full Text] [Related]
16. BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Sun X; He Y; Mao C; Zhu L; Qin X; Huang S
Leuk Lymphoma; 2014 Feb; 55(2):435-8. PubMed ID: 23772664
[No Abstract] [Full Text] [Related]
17. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil numerals.
Bitar C; Saba N
Blood; 2014 Mar; 123(11):1635. PubMed ID: 24761452
[No Abstract] [Full Text] [Related]
19. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.
Perna F; Abdel-Wahab O; Levine RL; Jhanwar SC; Imada K; Nimer SD
Haematologica; 2011 Feb; 96(2):342-3. PubMed ID: 21193423
[No Abstract] [Full Text] [Related]
20. Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
Zámecníkova A; Al Bahar S; Ramesh P
Cancer Genet Cytogenet; 2008 Jun; 183(2):109-13. PubMed ID: 18503829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
